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Abstract
Background: The Capripoxvirus, Lumpy skin disease virus (LSDV) has a restricted host-range and is being
investigated as a novel HIV-1 vaccine vector. LSDV does not complete its replication cycle in non-ruminant hosts.
Methods: The safety of LSDV was tested at doses of 10
4 and 10
6 plaque forming units in two strains of
immunocompromised mice, namely RAG mice and CD4 T cell knockout mice. LSDV expressing HIV-1 subtype C
Gag, reverse transcriptase (RT), Tat and Nef as a polyprotein (Grttn), (rLSDV-grttn), was constructed. The
immunogenicity of rLSDV-grttn was tested in homologous prime-boost regimens as well as heterologous prime-
boost regimes in combination with a DNA vaccine (pVRC-grttn) or modified vaccinia Ankara vaccine (rMVA-grttn)
both expressing Grttn.
Results: Safety was demonstrated in two strains of immunocompromised mice.
In the immunogenicity experiments mice developed high magnitudes of HIV-specific cells producing IFN-gamma
and IL-2. A comparison of rLSDV-grttn and rMVA-grttn to boost a DNA vaccine (pVRC-grttn) indicated a DNA prime
and rLSDV-grttn boost induced a 2 fold (p < 0.01) lower cumulative frequency of Gag- and RT-specific IFN-g CD8
and CD4 cells than a boost with rMVA-grttn. However, the HIV-specific cells induced by the DNA vaccine prime
rLSDV-grttn boost produced greater than 3 fold (p < 0.01) more IFN- gamma than the HIV-specific cells induced by
the DNA vaccine prime rMVA-grttn boost. A boost of HIV-specific CD4 cells producing IL-2 was only achieved with
the DNA vaccine prime and rLSDV-grttn boost. Heterologous prime-boost combinations of rLSDV-grttn and rMVA-
grttn induced similar cumulative frequencies of IFN- gamma producing Gag- and RT-specific CD8 and CD4 cells. A
significant difference (p < 0.01) between the regimens was the higher capacity (2.1 fold) of Gag-and RT-specific
CD4 cells to produce IFN-g with a rMVA-grttn prime - rLSDV-grttn boost. This regimen also induced a 1.5 fold
higher (p < 0.05) frequency of Gag- and RT-specific CD4 cells producing IL-2.
Conclusions: LSDV was demonstrated to be non-pathogenic in immunocompromised mice. The rLSDV-grttn
vaccine was immunogenic in mice particularly in prime-boost regimens. The data suggests that this novel vaccine
may be useful for enhancing, in particular, HIV-specific CD4 IFN- gamma and IL-2 responses induced by a priming
vaccine.
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HIV/AIDS is a major public health problem in many parts
of the world and the long term control of this disease will
only be obtained with an effective prophylactic vaccine [1].
The RV144 trial is the only phase 3 efficacy trial to have
tested a prime - boost combination, consisting of a recom-
binant canary poxvirus vector vaccine (ALVAC-HIV
expressed HIV-1 subtype B gag and protease as T-cell
immunogens and the gp120 of CRF01_AE strain) with a
recombinant glycoprotein 120 subunit vaccine (AIDSVAX
B/E) as the boost. This trial is the only one to demonstrate
some protection from HIV infection [2]. The other two
efficacy trials tested homologous prime-boost regimens
(gp120 protein [3] or a combination of adenovirus based
vaccines [4]) and showed no protection from HIV infec-
tion. These results confirm that HIV candidate vaccines
induce more effective immune responses when used in
heterologous prime - boost regimens [5,6].
Homologous prime-boost vaccination regimens are
n o ta se f f e c t i v ei ni n d u c i n gs t r o n gi m m u n er e s p o n s e s
partially due to the blunting effect of anti-vector immu-
nity [7,8]. There is some evidence that pre-immunity to
the poxvirus vectors results in lower immune responses.
For example, an attenuated vaccinia virus (VV) vector
expressing Japanese encephalitis virus (JEV) proteins
(NYVAC-JEV), induced neutralizing antibody responses
only in vaccinia-nonimmune recipients while vaccinia-
immune volunteers failed to develop protective JEV
antibodies. Another study with an HIV vaccine with
three DNA vaccine primes and an MVA boost demon-
strated that while pre-immunity to VV did not abolish
the immune response the magnitude of response was
lower than when there was no pre-immunity [9]. A
recent HIV vaccine phase 1 clinical trial investigated up
to five immunisations of MVA-HIV and fowlpox (FPV-
HIV) in homologous as well as heterologous prime-
boost vaccination regimens. It was demonstrated that
FPV-HIV alone was poorly immunogenic and that
MVA-HIV alone induced maximal responses after two
immunisations. T cell reponses were significantly
boosted in participants receiving the MVA-HIV priming
vaccination followed by the heterologous FPV-HIV
booster vaccination [10]. Prime-boost vaccination regi-
mens are also favourable as the memory T cells induced
by the secondary vaccination retain the effector memory
(TEM) phenotype longer than T cells generated by
priming alone [11]. Poxvirus vectors are particularly
good in combination with other vaccine vectors [12].
Therefore, there is a need for the identification of addi-
tional, antigenically distinct, nonpathogenic poxviruses
which could be used as vaccine vectors. These vectors
could be used in conjunction with other vectors to
boost immune responses to specific insert antigens, or
in the construction of vaccines against new diseases.
Although many vaccine vectors have been tested in
clinical trials and animal models there is no one ideal
vaccine vector that could be used to simultaneously pro-
tect against various diseases. Therefore, there is a need
for the discovery of novel vectors and the development
of improved vectors [13,14]. Many different research
groups are using the same vaccine vectors for many dif-
ferent antigens: however, the same vectors cannot be
used as vaccine vehicles for different diseases ad infini-
tum due to the anti-vector immunity. As they are
already in clinical trials, it is likely that poxvirus vaccine
vectors may be successful in HIV, tuberculosis [15] or
malaria prevention [16]. It will then depend on which
field gets efficacy data first as to which disease will get
first use of the vaccine vector. It is likely that this will
limit the use of that vector for other diseases. The num-
ber of poxvirus vectors being developed for clinical use
is limited to modified vaccinia Ankara (MVA) and the
avipoxviruses, fowlpox virus and canarypox virus, as
vectors for both prophylactic infectious disease vaccines
and cancer treatment [17-25].
Lumpy skin disease virus (LSDV), a capripoxvirus, is
the causal agent of lumpy skin disease (LSD) in cattle
[26]. The Neethling strain, which was attenuated in
1968 [27] is used extensively as a prophylactic vaccine
against LSD [27,28]. Recombinant LSDV is an effective
vaccine vector for veterinary diseases including rabies,
rift valley fever and heartwater [29-31]. LSDV does not
complete its replication cycle in non-ruminant hosts
[32] and therefore the attenuated Neethling strain is an
excellent candidate as a live replication-deficient vaccine
vector. We propose that LSDV could be used in humans
as a safe replication-deficient vaccine vector, in combi-
nation with a heterologous vector, such as MVA, in the
prevention of HIV-1.
Methods
Safety of LSDV in Immunocompromised Mice
All mouse procedures were approved by the University
of Cape Town Animal Research Ethics Committee. To
test the safety of wild-type LSDV, RAG mice (lacking
both T-cells and B-cells) and CD4 T cell knockout mice
(6-8 weeks old, 5 per group) were inoculated with 10
4
and 10
6 focus forming units (ffu) per mouse by the
intramuscular route, with 50 μl injected into each quad-
ricep muscle. Mouse weights and welfare with respect to
weight, appetite, coat condition and behaviour were
recorded daily for 4 weeks.
DNA vaccine, viruses and cells
The plasmid pVRC-grttnC (manufactured by Aldevron,
Fargo, ND, USA) expresses an HIV-1 subtype C poly-
protein consisting of Gag, RT, Tat and Nef (grttn) and
is a second generation DNA vaccine. It differs from the
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vector backbone has been replaced with the pVRC back-
bone provided by the Vaccine Research Center of the
National Institutes of Health, Bethesda, Maryland, USA
[34]. The HIV-1 genes (grttn) were modified for safety
issues, codon optimized for human expression [33] and
cloned downstream of the cytomegalovirus AD169
immediate-early promoter, with an enhancer intron A
and a Kozak sequence.
LSDV Neethling strain, a bovine vaccine, was provided
by Onderstepoort Veterinary Institute, South Africa.
MVA was obtained from Dr B. Moss (NIH, USA).
Foetal bovine testes cells (FBT) were isolated from
trypsinized foetal bovine testes [35] obtained from the
local abattoir. Madin-Darby bovine kidney epithelial
(MDBK) cells and Syrian baby hamster kidney (BHK-21)
cells were obtained from the American Type Culture
Collection (ATCC). Chick embryo fibroblast (CEF) cells
were isolated from 10-day old embryonated chicken
eggs and were maintained in 2% FCS and DMEM
(Gibco™).
Construction of transfer vectors for cloning into LSDV
and MVA
Plasmid pLW-51, (kindly provided by Linda Wyatt; NIH,
USA), was used as a backbone for the transfer vectors.
The HIV-1 genes were derived from recently trans-
mitted HIV-1 subtype C strains in South Africa [36].
For both the LSDV and MVA transfer vectors grttn was
cloned directly downstream of the vaccinia virus early/
late mH5 promoter. pLW-51grttn: Grttn was excised
from pJH-01 [37] using SalI followed by XmaCIa n d
cloned into the SalI and XmaCI sites of pLW-51 to gen-
erate pLW-51grttn. pYS-05: MVA flanking sequences in
pLW-51 were replaced with sequences from the non-
essential ribonucleotide reductase gene of LSDV [38].
LSDV flank I (LF1) and LSDV flank II (LFII), DNA frag-
ments of 508 bp and 552 bp respectively were PCR
amplified from LSDV DNA using the following primer
pairs:
LF1 forward: 5’-GAATTCATGGTATAAAATAAA-
ATGGAACC-3’;
LF1 reverse: 5’-GCGCGCCAAACGCTATTAATC-
GTTCTC-3’;
LF2 forward: 5’-CTGCAGTTGAGGGAATATTCTTT-
TCCGG-3’ and
LF2 reverse: 5’-AAGCTTGGTTATTCAAGATAAT-
TAACAAGAG-3’.
Restriction enzyme sites EcoRI and BssHII were
included at the beginning and end of LFI respectively;
PstIa n dHindIII were added at the beginning and end
of LFII respectively. Amplified fragments were cloned
into the SmaI site of pUC19 plasmid using a Rapid
DNA ligation kit (Roche, Germany). MVA flank I was
excised from pLW-51 with EcoRI and BssHII (Roche,
Germany) and replaced with LFI excised from pUC19
with the same restriction enzymes. MVA flank II was
then replaced with LFII using PstI and HindIII to gener-
ate plasmid pYS-03. Grttn [39] with an upstream Kozak
sequence was subcloned from pJH-01 [37] into the SalI
and XmaCI sites of pYS-03. The E.coli xanthine-guanine
phosphoribosyl transferase gene (Gpt) under the control
of the VV p7.5 promoter was excised from pGpt07/14
[40] on an EcoRI fragment, blunt-ended and cloned into
the blunt-ended XhoI restriction enzyme site.
Construction of rMVA-grttn
Chick embryo fibroblast (CEF) cells were infected with
wt MVA (NIH) (0.1 pfu/cell) and transfected with 500
ng pLW-51-Grttn linearized with NdeI. A lysate was
prepared 3 days later and used to infect BHK-21 cells.
Nine rounds of plaque picking were performed. The
final virus isolate expressed Grttn (indicated by positive
immunostaining with an anti-RT antibody(ARP428)
from the National Institute for Biological Standards and
Control (NIBSC) AIDS reagent program, United King-
dom) and was negative for GUS staining. rMVA-grttn
w a se x p a n d e di ne g g s( W e s t w o o det al., 1957) and the
titre determined in BHK-21 cells. MVA was detected
with a rabbit anti-vaccinia antibody (Biogenesis Ltd,
United Kingdom) and swine anti-rabbit HRP (Dako,
Denmark). Grttn expression was detected with sheep
anti-RT (ARP428) and rabbit anti-sheep HRP (Dako,
Denmark). Peroxidase was reacted with o-dianisidine
(Sigma-Aldrich, USA) in the presence of H2O2 to visua-
lize infected cells. Identical virus titres were obtained
irrespective of the antibody used to detect virus-infected
cells, indicating all MVA-infected cells expressed Grttn.
Preparation of rLSDV-grttn
FBT cells were infected with LSDV (0.1 ffu per cell) fol-
lowed by transfection with pYS-05 (400 ng). Twenty-
four hours later the medium was replaced with selection
medium (25 ug mycophenolic acid (MPA) (Sigma-
Aldrich, USA) and 250 ug xanthine (Sigma-Aldrich,
USA) per ml of 4% FCS in DMEM/Hams-F12 (Gibco,
USA)). The cells were cultured for 72 hours after which
a lysate was prepared for FBT cell infection and further
culture (72 hours) in selection medium for 3 passages.
Serial 10-fold dilutions of the final cell lysate were used
to infect 6-well plates of confluent FBT cells and blue
foci, detected by standard Gus staining, were picked 72h
later. Virus was released by freeze/thawing and the pro-
cess of infection and purification by focus picking was
performed eight times. A stock of rLSDV-grttn was pre-
pared from infected FBT cells, which were lysed 3 days
p.i. Following a low-speed centrifugation step to pellet
cell debris, the virus was pelleted through a 36% sucrose
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to determine the virus titre by staining with sheep anti-
RT (ARP428) and rabbit anti-sheep HRP (Dako, Den-
mark). Infected cells were visualized by adding o-Diani-
sidine (Sigma-Aldrich, USA) and hydrogen peroxide
(Sigma-Aldrich, USA).
PCR analysis
PCR was used to confirm the absence of wild-type
LSDV in the rLSDV-grttn preparation. Three primers
were designed: SQRR1, 5’-GTGGGCGTCAATGTT-
GAC-3’ binds specifically to a sequence immediately
upstream of the ribonucleotide reductase gene (insertion
site). SQGrttn3, 5’-GCTACTTCCCCGACTGGC-3’
binds specifically to sequences within and towards the 3’
end of the Grttn gene. Anti-sense primer SQRR2, 5’-
CATAAAATCAGTACATGCATCC-3’ binds specifically
to a sequence immediately downstream of the ribonu-
cleotide reductase gene. Confluent monolayers of FBT
cells were infected with rLSDV-grttn or wild-type LSDV
at a m.o.i of 0.05 pfu per cell. 48 hours post infection
lysates were prepared as described by [41]. PCR was
performed, using Pfu polymerase (Promega, USA), with
an initial denaturation step of 95°C for 2 minutes, fol-
l o w e db y3 5c y c l e so f9 5 ° Cf o r1m i n u t e ,5 5 ° Cf o r3 0
seconds and 73°C for 5 minutes; the final elongation
step was at 73°C for 7 minutes.
Immunofluorescence
FBT cells, grown on glass cover slips, were infected with
LSDV and/or transfected with pYS-05, and fixed after 24
hours with methanol-acetone (1:1). Grttn protein was
detected with sheep anti-p24 (Aalto Bioreagents Ltd., Ire-
land) and FITC conjugated donkey anti-sheep (Dako, Den-
mark) and viewed using a Zeiss fluorescence microscope.
Western blot Analysis to detect protein expression
Cell lysates were prepared 24 h after infection of FBT
cells with wild type LSDV (wt LSDV)or LSDVgrttn. For
detection of transient expression some wells were trans-
fected with pYS-05 follwing infection with wtLSDV.
Proteins were separated using 12% SDS polyacrylamide
gel electrophoreses and transferred to a nitrocellulose
membrane (Amersham Hybond™-P) using a semi-dry
blotting apparatus (Bio-Rad Laboratories, USA). Grttn
protein was detected by probing with sheep anti-RT
(ARP428) followed by anti-sheep IgG antibody conju-
gated with alkaline phosphatase and visualized with
NBT/BCIP (Roche, Germany).
Mouse immunizations
BALB/c mice (5 mice per group) were used for immune
response evaluation. Wild type LSDV (10
6 ffu or 10
4 ffu
in 100 μl PBS), rLSDV-grttn (10
6 ffu in 100 μlP B S ) ,
rMVA-grttn (10
6 plaque forming units (pfu) in 100 μl
PBS) or pVRC-grttn (100 μgD N Ai n1 0 0μlP B S ) ,w a s
administered by the intramuscular route, with 50 μl
injected into each quadricep muscle according to
approval of the UCT Animal Research Ethics
Committee.
IFN-g and IL-2 ELISPOT assays
IFN-g and IL-2 Gag- and RT- specific CD8+ and CD4+
T cells were detected using ELISPOT sets (BD Phar-
mingen) and splenocytes (pooled from 5 mice per
group) after red blood cell lysis [42,43]. Triplicate reac-
tions contained splenocytes (500 000 per well) in 200
μl R10 culture medium (RPMI with 10% heat inacti-
vated FCS, (Gibco, USA) containing 15 mM b-mercap-
toethanol, 100 U penicillin per ml, and 100 μg
streptomycin). Peptides (>95% pure; Bachem, Switzer-
land) AMQMLKDTI (GagCD8), NPPIPVGRIYKR-
WIILGLNK (GagCD4), VYYDPSKDLIA (RTCD8) and
PKVKQWPLTEVKIKALTAI (RTCD4) were used at 4
μg/ml. Reactions without peptide were included to
determine background responses. Peptide responses
are reported as spot-forming units (sfu) per 10
6 sple-
nocytes after subtraction of background responses.
Cumulative ELISPOT responses to Gag and RT were
calculated as the sum of responses to the individual
CD8+ and CD4+ T cell peptides.
Quantification of antigen-specific cytokine production
Splenocytes (7.5 × 10
6 per ml R10) were cultured for 24
hours with Gag and RT CD8 and CD4 peptides as used
in the IFN-g ELISPOT assay. IFN-g in the culture super-
natant was quantified using a flow cytometric bead
based assay (BD Pharmingen) and calculated as pg IFN-
g per 10
6 splenocytes [43]. IFN-g produced during sti-
mulation with the individual CD8+ and CD4+ T cell
peptides is expressed as cumulative IFN-g produced.
Pentamer staining
Splenocytes (5 × 10
6) were labeled for 30 min at 4°C
with APC-conjugated pentameric H-2D
k AMQMLKDTI
or H-2D
d VYYDPSKDLIA complexes (ProImmune,
Oxford) and PerCP-conjugated anti-CD8a (clone 53-6.7,
eBiosciences) [43]. Flow cytometry (FACScalibur with
CellQuest software (BD Biosciences)) was used to ana-
lyze pentameric-positive cells as a percentage of gated
CD8+ T cells.
Statistical analysis
Statistical tests were performed using 2-sample Student’s
t-test and one-way ANOVA test and p values of <0.05
were considered significant.
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Response of immunocompromised mice to LSDV
The weight fluctuations of RAG mice and CD4 T cell
knockout mice over 4 weeks after vaccination with 10
4
ffu or 10
6 ffu of wild-type LSDV was no different from
that of uninoculated mice or mice inoculated with PBS.
No changes in appetite, coat condition and behaviour
could be detected during the observation period after
vaccination of these mice with wild-type LSDV.
Construction of rLSDV-grttn and rMVA-grttn
Recombinant LSDV and MVA expressing Grttn, the
HIV-1 subtype C polyprotein comprising Gag, RT, Tat
and Nef [44], were constructed. Initially, transient
expression assays were performed to test for gene
expression from vaccinia virus promoters in LSDV-
infected FBT cells which were transfected with pYS-05.
Beta-glucuronidase (GUS) expression was detected 24
hours post infection of foetal bovine testes (FBT) cells
with LSDV and transfection with pYS-05 (Figure 1b).
No expression was observed in negative controls (unin-
fected cells; LSDV infected, non-transfected cells; unin-
fected, pYS-05 transfected cells). Transient expression of
Grttn (150kDa) using an anti-p24 antibody was observed
by immunofluorescence 24 hours post LSDV infection
a n dp Y S - 0 5t r a n s f e c t i o no fF B Tc e l l s( F i g u r e1 c ) .a n d
confirmed by western blot analysis (Figure 1d, lane 4).
After further passaging a stable recombinant rLSDV-
grttn was obtained and titrated in Madin-Darby bovine
kidney (MDBK) cells. Foci of infection were detected by
immunostaining for RT expression (Figure 2a). Expres-
sion of full length Grttn (150 kDa) was confirmed by
western blot analysis of lysates from virus-infected FBT
cells (Figure 2b, lane 4 (RT) and Figure 2c, lane 3
(Gag)). No Grttn expression was detected in wild type
LSDV infected cells (lanes 5 and 4 in Figures 2b and 2c
respectively). The absence of wild type LSDV in the pur-
ified rLSDV-grttn stock was confirmed by PCR (Figure
2d). The expected PCR DNA fragment sizes of 1.2 kb
and 1.4 kb were amplified from recombinant and wild
type virus lysates respectively. The absence of a 1.4 kb
fragment in rLSDV-grttn-infected cells (Figure 2d, lane
4) confirmed the absence of any residual wild type virus
present in the rLSDV-grttn stock.
rLSDV is immunogenic and boosts a primary DNA
vaccination
The immunogenicity of rLSDV-grttn was evaluated in
BALB/c mice using rLSDV-grttn alone as well as after
priming with the DNA vaccine pVRC-grttnC, which
expresses Grttn. Comparative experiments were per-
formed using rMVA-grttn and pVRC-grttnC.
A single vaccination with rLSDV-grttn induced a cumu-
lative IFN-g ELISPOT response of 224 sfu/10
6 splenocytes
(a)
   (b)                                            (c) 
(d) 
Figure 1 Construction of rLSDV-grttn. (a) transfer vector pYS-05.
LSDV infection (0.1 ffu/cell) and pYS-05 transfection (100 ng DNA)
of FBT cells and detection 24 hours later of (b) GUS using standard
staining procedures and (c) Grttn in the cytosol of the cells by
immunofluorescence using sheep anti-p24 and FITC conjugated
anti-sheep. (d) Western blot detection of Grttn in cell lysates using
sheep anti-RT and alkaline phosphatase conjugated anti-sheep. Lane
1, Molecular weight markers; Lane 2, pTHgrttnC (DNA) transfected
cells (positive control); Lane 3, RT positive control protein standard;
Lane 4, LSDV infected and pYS-05 transfected FBT cell lysate; Lane 5,
LSDV-infected FBT cells; Lane 6, pYS-05-transfected FBT cells; Lane 7,
uninfected FBT cells.
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(b)                                                            (c)
(d) 
Figure 2 Expression of Grttn in rLSDV-grttn infected FBT cells. (a) Immunostain of rLSDV-grttn-infected FBT cells incubated with RT specific
sheep antibody, followed by peroxidase conjugated anti-sheep immunoglobulin antibody. (100X magnification). (b) Western blot analysis of cell
lysates using sheep anti-RT and alkaline phosphatase conjugated anti-sheep. Lane 1, molecular weight markers; Lane 2, RT positive control
protein standard; Lane 3, rMVA-grttn infected BHK-21 cells; Lane 4, rLSDV-grttn-infected FBT cells; Lane 5, LSDV infected FBT cells (c) Western blot
analysis of cell lysates using sheep anti-p24 and alkaline phosphatase conjugated anti-sheep. Lane 1, molecular weight markers; Lane 2, Gag
positive control protein standard; Lane 3, rLSDV-grttn infected FBT cells; Lane 4, LSDV infected FBT cells. (d) PCR analysis of rLSDV-grttn using
primers designed to amplify a 1.4 kb fragment from the wild type LSDV and 1.2 kb fragment from the recombinant rLSDV-grttn. DNA products
were subjected to 1% agarose gel electrophoresis. Lane 1, DNA molecular weight standards with relevant sizes indicated to the left; Lane 2,
lysates of FBT cells; Lane 3, LSDV-infected FBT cells; Lane 4, rLSDV-grttn infected FBT cells.
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Gag. In comparison a single inoculation with rMVA-grttn
induced cumulative responses to Gag and RT CD8 and
CD4 peptides of 467 sfu/10
6 splenocytes (Figure 3a). Both
rLSDV-grttn and rMVA-grttn boosted the immune
response induced by a pVRC-grttn prime. A prime with
pVRC-grttn and boost with rLSDV-grttn induced a cumu-
lative Gag and RT CD8 and CD4 IFN-g ELISPOT
response of 747 sfu/10
6 splenocytes with 540 sfu/10
6 sple-
nocytes (72%) from CD8 cells. A significantly greater
response (p < 0.01) of 1567 sfu/10
6 splenocytes with 1139
sfu/10
6 splenocytes from CD8 cells (72%) was achieved
with a rMVA-grttn boost (Figuer 3a). These responses
were considerably greater (p < 0.01) than the cumulative
response of 107 sfu/10
6 splenocytes induced by two
pVRC-grttn vaccinations (Figure 3a).
The magnitude of IFN-g released from splenocytes
during culture with Gag and RT peptides was measured.
A pVRC-grttn prime and rLSDV-grttn boost produced a
total of 11470 pg IFN-g/10
6 splenocytes of which 45%
(5112 pg IFN-g/10
6 splenocytes) was from CD8 Gag-
and RT-specific cells. This is significantly (p < 0.01)
higher that a rMVA-grttn boost which induced a total
of 4816 pg IFN-g/10
6 splenocytes with 19% (884 pg
IFN-g/10
6 splenocytes) from CD8 Gag and RT-specific
cells (Figure 3b). The cumulative frequency of Gag- and
RT-specific CD4 and CD8 cells counted in the IFN-g
ELISPOT assay was collated with the level of IFN-g
released by these cells in culture as a further compari-
son of the regimens. Gag- and RT-specific CD8 and
CD4 cells induced by a DNA prime and rLSDV-grttn
boost were calculated to produce 9 and 31 pg IFN-g/
splenocyte respectively while these cells induced by a
DNA prime and rMVA-grttn boost were calculated to
produce 1 and 10 pg IFN-g/splenocyte respectively (Fig-
ure 3a and Figure 3b).
HIV-specific CD4 cells producing IL-2 were generated
by the individual poxvirus vaccines and by the DNA
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Figure 3 HIV-specific T cell responses to a DNA vaccine prime and boost with rLSDV-grttn or rMVA-grttn.G r o u p so fm i c ew e r e
vaccinated with the DNA vaccine pVRC-grttn then boosted on day 28 with the DNA vaccine, rLSDV-grttn or rMVA-grttn. Two other groups of
mice were vaccinated on day 28 with rLSDV-grttn or rMVA-grttn. Mice in all the groups were killed on day 40, 12 days after the final
immunization. Splenocytes, pooled from 5 mice per group, were used in the immunological assays. (a) IFN-g ELISPOT assay with Gag and RT
CD8 and CD4 peptides. Bars are the mean ± the SD of spot forming unit (sfu) from triplicate reactions for 10
6 splenocytes after subtraction of
background spots in the absence of peptide. (b), splenocytes were also cultured with the individual HIV CD8+ and CD4+ T cell peptides for 48 h
and culture supernatants were collected and IFN-g (pg cytokine/10
6 splenocytes) content quantified. The sum of IFN-g produced during
stimulation with the individual CD8+ and CD4+ T cell peptides was calculated and is presented as the cumulative total IFN-g produced by HIV-
specific CD8+ T cells or CD4+ T cells, values are indicated on the bars; and (c) IL-2 ELISPOT assay with pooled splenocytes and peptides as used
in the IFN-g ELISPOT assay. *: p < 0.01; **: p < 0.05. Data are from a representative experiment.
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Page 7 of 12vaccine prime and rLSDV-grttn or rMVA-grttn boost
vaccination regimens (Figure 3c). Only the DNA prime/
rLSDV-grttn boost regimen resulted in the cumulative
response to Gag and RT CD4 peptides (194 sfu/10
6
splenocytes) being greater than the sum of the cumula-
tive Gag and RT CD4 peptide responses for the indivi-
dual vaccines (p < 0.05) indicating a true boost of CD4
IL-2 producing cells by the DNA/rLSDV-grttn vaccine
regimen (Figure 3c).
Responses to heterologous combinations of rLSDV-grttn
and rMVA-grttn
The potential use of rLSDV-grttn in heterologous pox-
virus prime and boost vaccination regimens with rMVA-
grttn was investigated (Figure 4). A cumulative Gag and
R TC D 8a n dC D 4r e s p o n s eo f2 6 2 8s f u / 1 0
6 splenocytes
with 1000 sfu/10
6 splenocytes (64%) from responding
CD8+ T cells was measured in the IFN-g ELISPOT assay
for a prime with rMVA-grttn and a boost with rLSDV-
grttn (Figure 4a). This response was significantly greater
(p < 0.01) than the cumulative response of 795 sfu/10
6
splenocytes (68% CD8) achieved with a prime and boost
with rMVA-grttn (Figure 4a). The magnitude of a
rLSDV-grttn prime and rMVA-grttn boost was similar to
the reverse prime-boost with a cumulative Gag and RT
CD8 and CD4 response of 3066 sfu/10
6 splenocytes in
the IFN-g ELISPOT assay where 2214 sfu/10
6 splenocytes
(72%) were from responding CD8+ T cells. This was sig-
nificantly (p < 0.01) higher than a prime and boost with
rLSDV-grttn which generated 477 sfu/10
6 splenocytes
from only RT CD8 cells (Figure 4a).
The magnitude of IFN-g produced by Gag- and RT-
specific cells during culture was quantified for the het-
erologous poxvirus prime-boost vaccination regimens
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Figure 4 HIV-specific T cell responses to poxvirus vaccine prime and boost vaccination regimens.G r o u p so fm i c ew e r ep r i m e dw i t h
rLSDV-grttn or rMVA-grttn then boosted on day 28 with either rMVA-grttn or rLSDV-grttn as indicated on the y-axis. Mice in all the groups were
killed on day 40, 12 days after the final immunization. Splenocytes pooled from 5 mice per group were used in the immunological assays. (a)
IFN-g ELISPOT assay with Gag and RT CD8 and CD4 peptides. Bars are the mean ± the SD of spot forming unit (sfu) from triplicate reactions for
10
6 splenocytes after subtraction of background spots in the absence of peptide. (b), splenocytes were also cultured with the individual HIV CD8
+ and CD4+ T cell peptides for 48 h and culture supernatants were collected and IFN-g (pg cytokine/10
6 splenocytes) content quantified. The
sum of IFN-g produced during stimulation with the individual CD8+ and CD4+ T cell peptides was calculated and is presented as the cumulative
total IFN-g produced by HIV-specific CD8+ T cells or CD4+ T cells, values are indicated on the bars; and (c) IL-2 ELISPOT assay with pooled
splenocytes and peptides as used in the IFN-g ELISPOT assay; (d) pooled splenocytes were also labelled with APC-conjugated H-2D
k pentameric
complexes folded with the Gag AMQMLKDTI peptide or the RT peptide VYYDPSKDLIA and PerCP-conjugated anti-CD8a on day 28. Gag and RT
-specific MHC class I pentameric complex binding is expressed as a percentage of gated CD8+ T cells, percentages are indicated on the bars. *:
p < 0.01; **: p < 0.05. All data are from a representative experiment.
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Page 8 of 12(Figure 4b). A total of 63566 pg IFN-g/10
6 splenocytes
(with 14490 pg IFN-g/10
6 splenocytes (23%) from CD8
cells) was produced by a rMVA-grttn prime and
rLSDV-grttn boost (Figure 4b). A significantly (p < 0.01)
lower level of IFN-g (total of 37693 pg IFN-g/10
6 sple-
nocytes with 14568 pg IFN-g/10
6 splenocytes (39%)
from Gag and RT CD8 cells) was induced by a rLSDV-
grttn prime and rMVA-grttn boost. Comparing the het-
erologous prime-boost vaccine regimens in terms of
levels of cytokines produced by individual splenocytes
related to frequency of responding cells in the IFN-g
ELISPOT assay, for a rMVA-grttn prime and rLSDV-
grttn boost, 7 pg and 53 pg IFN-g were produced per
responding Gag- and RT-specific CD8+ and CD4+ T
cell respectively. In contrast Gag and RT-specific CD8+
and CD4+ T cells for a rLSDV-grttn prime and rMVA-
grttn boost produced 9 pg IFN-g and 28 pg IFN-g per
responding cell respectively (Figure 4a and 4b). Thus
the rMVA-grttn prime and rLSDV-grttn boost regimen
induced HIV-specific CD4+ T cells with a higher capa-
city to produce IFN-g than a rLSDV-grttn prime and
rMVA-grttn boost.
G a ga n dR TC D 4I L - 2E L I S P O Tr e s p o n s e sw e r e
detected for the heterologous prime-boost vaccination
regimens (Figure 4c). The cumulative IL-2 ELISPOT
response for rMVA-grttn prime and rLSDV-grttn boost
reached 684 sfu/10
6 splenocytes. This response was 450
sfu/10
6 splenocytes for a rLSDV-grttn prime and
rMVA-grttn boost (Figure 4c).
Binding of H-2D
k AMQMLKDTI or H-2D
d
VYYDPSKDLIA complexes to CD8+ T cells indicated
both heterologous poxvirus vaccination regimens
induced high frequencies of HIV-specific CD8+ T cells
(Figure 4d). When rLSDV-grttn was the booster vaccine
the sum of Gag- and RT- specific CD8 cells reached a
frequency of 4.6% of the CD8 cells while this frequency
was 7% of the CD8 cells when rMVA-grttn was the
booster vaccine (P < 0.05; Figure 4d). Approximately
98% of these HIV-specific CD8 cells for both vaccina-
tion regimens expressed CD44 confirming these cells to
be antigen experienced.
Insight into the fraction of total HIV-specific CD8
cells in the spleen that produce IFN-g in response to the
poxvirus prime and boost regimens was obtained by
comparing the pentameric H-2D peptide complex bind-
ing data with the frequency of Gag- and RT-specific
CD8 cells detected in the IFN-g ELISPOT assay. For
this the cumulative frequencies of Gag- and RT-specific
CD8 cells determined in the IFN-g ELISPOT assay was
expressed as a percentage of the total CD8 population
(136000 CD8 cells/10
6 splenocytes) in the spleen. When
rLSDV-grttn was the booster vaccine HIV-specific CD8
cells responding in the IFN-g ELISPOT assay was calcu-
lated to be 1.9% of the CD8 population in the spleen.
This figure was calculated to be 2.2% of the CD8 popu-
lation in the spleen when rMVA-grttn was the booster
vaccine. It thus appears if these figures are compared to
the direct enumeration of HIV-specific CD8 cells using
H-2D peptide complex binding that these vaccine regi-
mens induce HIV-specific CD8 cells that produce more
than HIV-specific IFN-g producing cells.
Discussion
LSDV (Neethling) has a long history of safety in animals
as a veterinary vaccine. This, together with its restricted
host range properties, makes it attractive as a potential
safe vaccine vector for an HIV vaccine. Our experiments
demonstrated LSDV safety in immunocompromised
( R A Ga n dC D 4k n o c k o u t)m i c ea t1 0
4 and 10
6 ffu per
mouse. This is a similar safety profile as reported in
immunodeficient mice for MVA, although it should be
n o t e dt h a tM V Aw a sa l s ot e s t e da tah i g h e rt i t r eo f1 0
9
[45]. These results indicate that the vectors should be
safe in humans at similar doses.
A potential disadvantage is that lumpy skin disease is
confined to Africa and Asia, suggesting the LSDV vector
may be limited to use in these two continents. However,
the enormous extent of the public health problem
caused by HIV in Southern Africa and the urgency with
which vaccine intervention is required in this region jus-
tifies the development of this African HIV vaccine vec-
tor. Although LSDV grows optimally in primary FBT
cells, these cells would probably not be approved by reg-
ulatory bodies for the mass production of an HIV-1 vac-
cine. An alternative approach to the large scale growth
of LSDV would be to grow the virus on the chorioallan-
toic membranes (CAMs) of fertilized hens’ eggs or pri-
mary egg cell culture. The Neethling strain of LSDV
was attenuated by passage of the virus both in primary
cells as well as on the CAMs of fertilized eggs [28].
Poxvirus based vaccines are known to activate both
humoral and cellular immune responses [46]. The
immunological correlates of protection against HIV have
not been identified but there is increasing evidence from
animal studies and T-cell responses to HIV that T cell
participation is involved [47-49]. This is also supported
by correlations between HIV specific CTL and the con-
trol of disease progression observed in certain long-term
non progressing HIV-1 infected individuals [50,51].
Excellent safety features of MVA are promoting endea-
vours concentrating on developing new MVA constructs
with improved immunogenicity [52]. The data in this
study indicated rLSDV-grttn is immunogenic with a sin-
gle vaccination inducing HIV specific IFN-g and IL-2
HIV-specific CD8+ and CD4+ T cells. An important
finding is the suggestion that rLSDV-grttn can be used
successfully as a booster vaccine. Boosted responses
were achieved after a prime with either a DNA vaccine,
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Page 9 of 12pVRC-grttn, or rMVA-grttn vaccine and boost with
rLSDV-grttn. In this study a comparison was made
between using rLSDV-grttn and rMVA-grttn as the
booster vaccines. The frequency of total HIV-specific
IFN-g positive T cells in response to a DNA prime and
rLSDV-grttn boost was lower than that of a DNA prime
and rMVA-grttn boost regimen. When the level of IFN-
g released by the HIV-specific CD8+ and CD4+ T cells
during culture with the HIV peptides and the frequency
of cells responding to these peptides in the IFN-g ELI-
SPOT assay was compared it appears that the HIV-spe-
cific cells have a greater capacity by a factor of 2 to
produce IFN-g when rLSDV-grttn is the booster vaccine
than when rMVA-grttn is the booster vaccine. A further
contrast between the use of rLSDV-grttn and rMVA-
grttn as the booster vaccine is the finding that the total
T cell IFN-g production is equally from CD8+ and CD4
+ T cells when rLSDV-grttn is the booster vaccine but
predominantly produced by CD8+ T cells when rMVA-
grttn is the booster vaccine.
Although homologous boosting with rLSDV-grttn
and rMVA-grttn did yield improved responses over
that of a single vaccination with each of these poxvirus
vaccines, a much improved response was obtained if
the poxvirus vaccines were used in heterologous
prime-boost vaccination regimens. Both heterologous
poxvirus vaccine regimens induced high frequencies of
HIV-specific CD8 cells as determined by binding of
pentameric H-2D complexes folded with the Gag and
RT CD8 peptides to CD8 cells in the spleen. These
HIV-specific CD8+ T cells expressed CD44 confirming
these cells to be antigen experienced. IFN- g and IL-2
ELISPOT assays indicated cells producing IFN-g or IL-
2 were induced. A boost with either rLSDV-grttn or
rMVA-grttn induced similar frequencies of HIV-speci-
fic CD8+ and CD4+ IFN-g or IL-2 producing T cells.
However, the more potent heterologous prime-boost
inoculation regimen with respect to IFN-g production
was identified by quantifying the level of IFN-g
released by the HIV-specific T cells during culture
with the HIV peptides. The HIV-specific CD8 and
CD4 cells induced by a prime with rMVA-grttn and
boost with rLSDV-grttn produced 1.7 fold more IFN-g
into culture supernatants than the reverse inoculation
regimen. The difference between the regimens is attri-
butable to increased IFN-g production by HIV-specific
CD4 cells by the rMVA-grttn prime and rLSDV-grttn
boost regimen. Responses to rLSDV-grttn appear to be
biased towards CD4 cell responses. For both heterolo-
gous poxvirus inoculation regimens the HIV-specific
CD8 cells produced approximately equal levels of IFN-
g per HIV -specific CD8 cell. However the CD4 cells
from the rMVA-grttn prime and rLSDV-grttn boost
regimen produced almost twice more IFN-g per HIV
-specific CD4 T cell than the rLSDV-grttn prime and
rMVA-grttn boost.
Conclusions
These results indicate that LSDV (Neethling) could well
be a promising novel vaccine vector for use in Africa as
an HIV-1 vaccine. We have shown it to be effectively
immunogenic in mice, especially as a booster vaccine.
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